Cite
HARVARD Citation
Rosen, N. et al. (2018). 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies. Headache. 58 (9), pp. 1347-1357. [Online].